-
Millennium Pharmaceuticals Inc. v. Mylan Laboratories Limited et al. DC CAFC
- 1:15-cv-00040
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 01/14/2015
- Closed: 04/09/2018
- Latest Docket Entry: 04/10/2018
- PACER
1
Plaintiff
3
Defendants
1
Accused
Product
2
Patents-in-Suit
1,182
Days in
Litigation
-
Millennium Pharmaceuticals Inc. v. Mylan Laboratories Limited et al. DC CAFC
- 1:15-cv-00040
- D. Del.
- Judge: Gregory M. Sleet
- Filed: 01/14/2015
- Closed: 04/09/2018
- Latest Docket Entry: 04/10/2018
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim | Outcome |
|---|---|
| All challenged claims |
Invalid (103)
Entry 20 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 20 |
The lyophilized compound D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Invalid (103)
Entry 20 |
| 31 |
The method of claim 23, wherein the compound of formula (1) is D-mannitol N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronate.
|
Invalid (103)
Entry 20 |
| 49 |
A lyophilized cake comprising the compound of claim 20.
|
Invalid (103)
Entry 20 |
| 53 |
The method of claim 31 further comprising (c) reconstituting the lyophilized mixture with a pharmaceutically-acceptable carrier.
|
Invalid (103)
Entry 20 |
-
Infringement
Agila Specialties Inc.
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injectionGeneric 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 27Entry 20 |
| Generic 3.5 mg/vial bortezomib for injection | US 6,958,319 B2 | All Asserted Claims |
No infringement
Entry 20
|
Mylan Laboratories Limited
- 2 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 3.5 mg/vial bortezomib for injectionGeneric 3.5 mg/vial bortezomib for injection | US 6,713,446 B2 |
20, 31, 49, 53
|
Infringement
Entry 27Entry 20 |
| Generic 3.5 mg/vial bortezomib for injection | US 6,958,319 B2 | All Asserted Claims |
No infringement
Entry 20
|